Buyers and sellers in the transaction are not officially known.
On Thursday, June 19
, CNCB-TV18 reported, citing sources that private equity firm TPG Asia is likely to divest a 6% stake in the contract research and manufacturing company via block deals.
Sources had said the sale would involve approximately 12.5 million shares at a base price of ₹710 per share. The total deal size was estimated around $102 million.
There would be a 60-day lock-in period for the seller post transaction.
At the end of the March quarter, TPG Asia held 24.73% stake in the company.
Last month, Sai Life Sciences said it expected a compound annual growth rate (CAGR) of 15-20% in revenues over the next 3-5 years, along with an increase in margins from 24% to 30%.
Siva Chittor, CFO of Sai Life Sciences, said, “A large portion of this will come from operating leverage on a counter expansion in the business. That is really what we are seeing today. If you look at what we did last year, we were a little about 20%, and then we ended this year at 25%.”
He said achieving 20% compound annual growth in revenue and 25% in EBITDA is possible, but growth in the CDMO sector tends to be uneven. Some years may see slower momentum, while others could deliver stronger results.
In the March quarter, the company reported a revenue of ₹579 crore, margins of 27.2%, and a profit of ₹88 crore.
Sai Life shares were down 0.3% at ₹725.7 apiece at 9.30 am at 9.25 am on Friday, June 20. The stock has declined 4.5% this year, so far.
Also Read: HAL Dividend Alert: PSU compounder to declare final payout after 17% surge so far in 2025
First Published: Jun 20, 2025 9:32 AM IST
